» Articles » PMID: 35743985

Patients with Invasive Lobular Carcinoma Show a Significant Increase in IRS-4 Expression Compared to Infiltrative Ductal Carcinoma-A Histopathological Study

Abstract

Breast cancer (BC) is the first diagnosed type of cancer and the second leading cause of cancer-related mortality in women. In addition, despite the improvement in treatment and survival in these patients, the global prevalence and incidence of this cancer are rising, and its mortality may be different according to the histological subtype. Invasive lobular carcinoma (ILC) is less common but entails a poorer prognosis than infiltrative ductal carcinoma (IDC), exhibiting a different clinical and histopathological profile. Deepening study on the molecular profile of both types of cancer may be of great aid to understand the carcinogenesis and progression of BC. In this sense, the aim of the present study was to explore the histological expression of Insulin receptor substrate 4 (IRS-4), cyclooxygenase 2 (COX-2), Cyclin D1 and retinoblastoma protein 1 (Rb1) in patients with ILC and IDC. Thus, breast tissue samples from 45 patients with ILC and from 45 subjects with IDC were analyzed in our study. Interestingly, we observed that IRS-4, COX-2, Rb1 and Cyclin D1 were overexpressed in patients with ILC in comparison to IDC. These results may indicate a differential molecular profile between both types of tumors, which may explain the clinical differences among ILC and IDC. Further studies are warranted in order to shed light onto the molecular and translational implications of these components, also aiding to develop a possible targeted therapy to improve the clinical management of these patients.

Citing Articles

Advances in Cancer Therapy from Research to Clinical Practice-Surgical, Molecular or Systemic Management of Cancer.

Cainap C, Crisan N Medicina (Kaunas). 2023; 59(7).

PMID: 37512120 PMC: 10385133. DOI: 10.3390/medicina59071309.

References
1.
Singh-Ranger G, Salhab M, Mokbel K . The role of cyclooxygenase-2 in breast cancer: review. Breast Cancer Res Treat. 2007; 109(2):189-98. DOI: 10.1007/s10549-007-9641-5. View

2.
Du T, Zhu L, Levine K, Tasdemir N, Lee A, Vignali D . Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. Sci Rep. 2018; 8(1):7205. PMC: 5940770. DOI: 10.1038/s41598-018-25357-0. View

3.
Ortega M, Fraile-Martinez O, Pekarek L, Alvarez-Mon M, Asunsolo A, Sanchez-Trujillo L . Defective expression of the peroxisome regulators PPARα receptors and lysogenesis with increased cellular senescence in the venous wall of chronic venous disorder. Histol Histopathol. 2021; 36(5):547-558. DOI: 10.14670/HH-18-322. View

4.
Ortega M, Fraile-Martinez O, Guijarro L, Casanova C, Coca S, Alvarez-Mon M . The Regulatory Role of Mitochondrial MicroRNAs (MitomiRs) in Breast Cancer: Translational Implications Present and Future. Cancers (Basel). 2020; 12(9). PMC: 7564393. DOI: 10.3390/cancers12092443. View

5.
Harris R, Casto B, Harris Z . Cyclooxygenase-2 and the inflammogenesis of breast cancer. World J Clin Oncol. 2014; 5(4):677-92. PMC: 4129532. DOI: 10.5306/wjco.v5.i4.677. View